Home › Castration-Resistant Prostatic Cancer
Castration-Resistant Prostatic Cancer clinical trials recruiting in the U.S.
18 studies for Castration-Resistant Prostatic Cancer are recruiting participants at sites across the United States.
Cities with the most studies
- Los Angeles, CA8 studies
- New York City, NY7 studies
- Houston, TX6 studies
- Seattle, WA6 studies
- Boston, MA5 studies
- Queens, NY4 studies
- Pittsburgh, PA4 studies
- Philadelphia, PA4 studies
- Grand Rapids, MI3 studies
- San Francisco, CA3 studies
- Cincinnati, OH3 studies
- Baltimore, MD3 studies
- Nashville, TN3 studies
- St. Louis, MO3 studies
- Dallas, TX3 studies
- Minneapolis, MN3 studies
- Myrtle Beach, SC3 studies
- Mountain View, CA3 studies
- Arlington, VA3 studies
- Metairie, LA3 studies
- San Diego, CA3 studies
By state
- California11 studies
- Connecticut3 studies
- Florida5 studies
- Illinois3 studies
- Louisiana3 studies
- Maryland3 studies
- Massachusetts5 studies
- Michigan7 studies
- Minnesota4 studies
- Missouri3 studies
- Nebraska3 studies
- New Jersey4 studies
- New York8 studies
- North Carolina4 studies
- Ohio4 studies
- Oregon3 studies
- Pennsylvania5 studies
- South Carolina4 studies
- Tennessee5 studies
- Texas7 studies
- Virginia4 studies
- Washington6 studies
Recently updated studies
A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study in Patients With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 24, 2026 · NCT07719361A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06863272Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06353386Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
RecruitingPhase 1
Ages 18 and older · Men · Updated Sep 10, 2026 · NCT05997615A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT04104776Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449A Study of MGC026 in Participants With Advanced Solid Tumors
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 11, 2026 · NCT06242470A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer
RecruitingPhase 1
Ages 18 and older · Men · Updated Aug 10, 2026 · NCT06067841A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer
RecruitingObservational study
Ages 18 to 115 · Men · Updated Jul 16, 2026 · NCT07677254A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan
RecruitingObservational study
Ages 18 to 115 · Men · Updated Jul 16, 2026 · NCT07677267A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer
RecruitingPhase 1/2
Ages 18 and older · Men · Updated May 29, 2026 · NCT0725840764Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
RecruitingPhase 1/2
Ages 18 and older · Men · Updated May 6, 2026 · NCT04868604Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1/2
Ages 18 and older · Men · Updated Apr 13, 2026 · NCT06190899Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
RecruitingPhase 2
Ages 18 and older · Men · Updated Apr 13, 2026 · NCT04337580Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer
RecruitingPhase 1
Ages 18 and older · Men · Updated Nov 21, 2025 · NCT0574362118F-Fluciclovine PET/CT Impact on Predicting Clinical Outcome of 177Lu-PSMA-617 Therapy in Patients With Prostate Cancer
RecruitingPhase 4
Ages 18 and older · Men · Updated Nov 27, 2024 · NCT06706921From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.